Literature DB >> 20722672

Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study.

L A Sargeant1, R K Simmons, R S Barling, R Butler, K M Williams, A T Prevost, A L Kinmonth, N J Wareham, S J Griffin.   

Abstract

AIMS: One of the factors influencing the cost-effectiveness of population screening for Type 2 diabetes may be uptake. We examined attendance and practice- and individual-level factors influencing uptake at each stage of a diabetes screening programme in general practice.
METHODS: A stepwise screening programme was undertaken among 135, 825 people aged 40-69 years without known diabetes in 49 general practices in East England. The programme included a score based on routinely available data (age, sex, body mass index and prescribed medication) to identify those at high risk, who were offered random capillary blood glucose (RBG) and glycosylated haemoglobin tests. Those screening positive were offered fasting capillary blood glucose (FBG) and confirmatory oral glucose tolerance tests (OGTT).
RESULTS: There were 33 539 high-risk individuals invited for a RBG screening test; 24 654 (74%) attended. Ninety-four per cent attended the follow-up FBG test and 82% the diagnostic OGTT. Seventy per cent of individuals completed the screening programme. Practices with higher general practitioner staff complements and those located in more deprived areas had lower uptake for RBG and FBG tests. Male sex and a higher body mass index were associated with lower attendance for RBG testing. Older age, prescription of antihypertensive medication and a higher risk score were associated with higher attendance for FBG and RBG tests.
CONCLUSIONS: High attendance rates can be achieved by targeted stepwise screening of individuals assessed as high risk by data routinely available in general practice. Different strategies may be required to increase initial attendance, ensure completion of the screening programme, and reduce the risk that screening increases health inequalities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722672      PMCID: PMC3428846          DOI: 10.1111/j.1464-5491.2010.03056.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  34 in total

1.  The performance of a risk score in predicting undiagnosed hyperglycemia.

Authors:  P J Park; S J Griffin; L Sargeant; N J Wareham
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

2.  The determinants of screening uptake and interventions for increasing uptake: a systematic review.

Authors:  R Jepson; A Clegg; C Forbes; R Lewis; A Sowden; J Kleijnen
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

3.  Effect of multiple patient reminders in improving diabetic retinopathy screening. A randomized trial.

Authors:  R J Halbert; K M Leung; J M Nichol; A P Legorreta
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

4.  Colorectal cancer screening participation: comparisons with mammography and prostate-specific antigen screening.

Authors:  S Lemon; J Zapka; E Puleo; R Luckmann; L Chasan-Taber
Journal:  Am J Public Health       Date:  2001-08       Impact factor: 9.308

5.  The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening.

Authors:  T Lauritzen; S Griffin; K Borch-Johnsen; N J Wareham; B H Wolffenbuttel; G Rutten
Journal:  Int J Obes Relat Metab Disord       Date:  2000-09

6.  Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability.

Authors:  P J O'Connor; W A Rush; L M Cherney; N P Pronk
Journal:  Eff Clin Pract       Date:  2001 Nov-Dec

7.  GP and patient predictors of PSA screening in Australian general practice.

Authors:  Melina Gattellari; Jane M Young; Jeanette E Ward
Journal:  Fam Pract       Date:  2003-06       Impact factor: 2.267

8.  Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile.

Authors:  Annemieke M W Spijkerman; Marcel C Adriaanse; Jacqueline M Dekker; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

9.  What determines the cost-effectiveness of diabetes screening?

Authors:  C Glümer; M Yuyun; S Griffin; D Farewell; D Spiegelhalter; A L Kinmonth; N J Wareham
Journal:  Diabetologia       Date:  2006-04-26       Impact factor: 10.122

10.  Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial.

Authors:  Helen C Eborall; Simon J Griffin; A Toby Prevost; Ann-Louise Kinmonth; David P French; Stephen Sutton
Journal:  BMJ       Date:  2007-08-30
View more
  33 in total

1.  Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study.

Authors:  D R Webb; L J Gray; K Khunti; B Srinivasan; N Taub; S Campbell; J Barnett; A Farooqi; J B Echouffo-Tcheugui; S J Griffin; N J Wareham; M J Davies
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort.

Authors:  R K Simmons; M Rahman; R W Jakes; M F Yuyun; A R Niggebrugge; S H Hennings; D R R Williams; N J Wareham; S J Griffin
Journal:  Diabetologia       Date:  2010-10-27       Impact factor: 10.122

3.  Risk scores for predicting type 2 diabetes: using the optimal tool.

Authors:  M Alssema; D Vistisen; M W Heymans; G Nijpels; C Glümer; P Z Zimmet; J E Shaw; M Eliasson; C D A Stehouwer; A G Tabák; S Colagiuri; K Borch-Johnsen; J M Dekker
Journal:  Diabetologia       Date:  2011-06-10       Impact factor: 10.122

4.  Spousal cardiometabolic risk factors and incidence of type 2 diabetes: a prospective analysis from the English Longitudinal Study of Ageing.

Authors:  Jannie Nielsen; Adam Hulman; Daniel R Witte
Journal:  Diabetologia       Date:  2018-03-08       Impact factor: 10.122

5.  Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort.

Authors:  Morten Charles; Rebecca K Simmons; Kate M Williams; Gojka Roglic; Stephen J Sharp; Ann-Louise Kinmonth; Nicholas J Wareham; Simon J Griffin
Journal:  Br J Gen Pract       Date:  2012-06       Impact factor: 5.386

6.  The influence of non-response in a population-based cohort study on type 2 diabetes evaluated by the Swedish Prescribed Drug Register.

Authors:  Anna-Karin Eriksson; Anders Ekbom; Agneta Hilding; Claes-Göran Ostenson
Journal:  Eur J Epidemiol       Date:  2011-11-17       Impact factor: 8.082

Review 7.  The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps.

Authors:  Bernadette Thomas
Journal:  Curr Diab Rep       Date:  2019-03-02       Impact factor: 4.810

8.  Long-term effect of population screening for diabetes on cardiovascular morbidity, self-rated health, and health behavior.

Authors:  Justin B Echouffo-Tcheugui; Rebecca K Simmons; A Toby Prevost; Kate M Williams; Ann-Louise Kinmonth; Nicholas J Wareham; Simon J Griffin
Journal:  Ann Fam Med       Date:  2015-03       Impact factor: 5.166

9.  Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance.

Authors:  Byron P Olson; Nathaniel I Matter; Marwood N Ediger; Edward L Hull; John D Maynard
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

Review 10.  The Need for Patient Follow-up Strategies to Confirm Diabetes Mellitus in Large Scale Opportunistic Screening.

Authors:  A K Savitha; S Gopalakrishnan; R Umadevi; R Rama
Journal:  J Clin Diagn Res       Date:  2016-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.